Philippe Duchateau - Cellectis Chief Scientific Officer
| CLLS Stock | USD 1.87 0.01 0.54% |
Executive
Dr. Philippe Duchateau has served as Chief Scientific Officer and Member of Executive Committee at Cellectis SA since January 30, 2012. He joined the Company in 2001 and he served as Head of Research Department from 2004. After receiving his Ph.D. in 1993 in biochemistry and molecular biology at the Institut Pasteur, he completed a research fellowship from 1993 to 2001 at the University of California, San Francisco within the Cardiovascular Research Institute. He is coinventor of numerous patents in the field of nucleases and gene editing and coauthor on more than 50 scientific publications and coeditor of one book entitled Sitedirected Insertion of Transgenes. since 2012.
| Age | 61 |
| Tenure | 12 years |
| Professional Marks | Ph.D |
| Address | 8, rue de la Croix Jarry, Paris, France, 75013 |
| Phone | 33 1 81 69 16 00 |
| Web | https://www.cellectis.com |
Cellectis Management Efficiency
The company has return on total asset (ROA) of (0.1609) % which means that it has lost $0.1609 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.822) %, meaning that it created substantial loss on money invested by shareholders. Cellectis' management efficiency ratios could be used to measure how well Cellectis manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.32 in 2024. Return On Capital Employed is likely to drop to -0.57 in 2024. At this time, Cellectis' Other Current Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 243.1 M in 2024, whereas Total Assets are likely to drop slightly above 270.8 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Eddie MBA | Lumos Pharma | N/A | |
| Caroline Holda | Seres Therapeutics | N/A | |
| Steve Parsons | Scpharmaceuticals | N/A | |
| JD Esq | Seres Therapeutics | 69 | |
| RPh Young | Seres Therapeutics | 57 | |
| Nicole Esq | HCW Biologics | N/A | |
| Nishi MD | Eliem Therapeutics | N/A | |
| Matthew Henn | Seres Therapeutics | 49 | |
| Rachael Nokes | Scpharmaceuticals | 49 | |
| Valerie Morisset | Eliem Therapeutics | 54 | |
| MD MBA | Eliem Therapeutics | 50 | |
| Roshan Girglani | Milestone Pharmaceuticals | N/A | |
| Lisa MD | Seres Therapeutics | 65 | |
| Alpa Parikh | Lumos Pharma | N/A | |
| David Ege | Seres Therapeutics | 49 | |
| Michael Hassman | Scpharmaceuticals | N/A | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
| Carlo Tanzi | Seres Therapeutics | N/A | |
| Kim Fox | Milestone Pharmaceuticals | N/A | |
| John PharmD | Scpharmaceuticals | N/A | |
| Lee Flowers | HCW Biologics | 78 | |
Management Performance
| Return On Equity | -0.82 | ||||
| Return On Asset | -0.16 |
Cellectis SA Leadership Team
Elected by the shareholders, the Cellectis' board of directors comprises two types of representatives: Cellectis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cellectis. The board's role is to monitor Cellectis' management team and ensure that shareholders' interests are well served. Cellectis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cellectis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andre Choulika, Chairman of the Board and CEO, Member of the Executive Committee | ||
| MarieBleuenn Terrier, General Counsel, Member of the Executive Committee | ||
| Dr MBA, Chief Officer | ||
| David Sourdive, Co-Founder, Executive VP of Corporate Devel. and Director | ||
| Valerie Cros, Principal Officer | ||
| Kyung NamWortman, Executive Officer | ||
| Philippe Duchateau, Chief Scientific Officer | ||
| Pascalyne Wilson, Director Communications | ||
| Stephan MSc, Chief Officer | ||
| Jean Epinat, Chief Officer | ||
| MSc MSc, Chief Officer | ||
| Arthur Stril, Interim Officer |
Cellectis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cellectis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.82 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (2.34) % | ||||
| Operating Margin | (0.60) % | ||||
| Current Valuation | 11.48 M | ||||
| Shares Outstanding | 100.09 M | ||||
| Shares Owned By Insiders | 3.86 % | ||||
| Shares Owned By Institutions | 14.60 % | ||||
| Number Of Shares Shorted | 156.19 K | ||||
| Price To Earning | (14.84) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cellectis Stock Analysis
When running Cellectis' price analysis, check to measure Cellectis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectis is operating at the current time. Most of Cellectis' value examination focuses on studying past and present price action to predict the probability of Cellectis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectis' price. Additionally, you may evaluate how the addition of Cellectis to your portfolios can decrease your overall portfolio volatility.